港股異動 | 微盟集團(2013.HK)升超5%續創新高 今年累計漲幅超260%
格隆匯7月8日丨微盟集團(2013.HK)現漲5.2%,報12.32港元續創新高,暫成交3.7億港元,最新總市值275.8億港元。今年以來股價持續上漲,累計漲幅超260%。在6月底獲貝萊德增持涉資約7332.39萬港元。因疫情影響,未來線下商業生態將認識到互聯網工具重要性,進一步擁抱移動互聯網。微盟作為騰訊社交生態廣告體系中龍頭企業,擁有豐富研發經驗及數據積累,未來必將充分享受市場紅利。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.